anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
MAIA Biotechnology · pitchdeck

MAIA Biotechnology | Investor Presentation Deck | 31 slides

31 pages · 6 arc beats · 2 loops

Pitchdeck Download JSON
Unlock

MAIA Biotechnology | Investor Presentation Deck | 31 slides

MAIA Biotechnology · 2024-01
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

6
coverage by narrative range · generated from this deck JSON
Narrative range 6 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 5 hits
— 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides Solution 1 slides 100% 1/1 slides 100% 1/1 slides · 2 hits
— 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides Market Size 1 slides 100% 1/1 slides 100% 1/1 slides · 7 hits
— 0/1 slides
100% 1/1 slides
— 0/1 slides
100% 1/1 slides
— 0/1 slides
Competition 1 slides 100% 1/1 slides 100% 1/1 slides · 4 hits
— 0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides
— 0/1 slides
Team 1 slides 100% 1/1 slides 100% 1/1 slides · 8 hits
— 0/1 slides
100% 1/1 slides
— 0/1 slides
100% 1/1 slides
— 0/1 slides
The Ask 1 slides 100% 1/1 slides 100% 1/1 slides · 3 hits
— 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides
— 0/1 slides

Slide inventory

31
every slide · same image gating as the playbook
01
Slide 1
The background image appears to be a microscopic view of chromosomes or cellular structures, reinforcing the 'telomere' focus.front_matter
Open slide detail
02
other
Open slide detail
03
The slide outlines the status of THIO-101, 102, and 103, highlighting FDA designations and clinical trial progress.summarize
Open slide detailBeat · The Ask
04
The slide uses a custom timeline/pipeline layout to show drug development stages.plan_implementation
Open slide detail
05
transition
Open slide detail
06
The slide uses a three-column layout with circular callouts to emphasize demographic trends and disease prevalence.frame_problem
Open slide detailBeat · ProblemLoop · Why Now
07
This is a transition or thesis slide emphasizing competitive differentiation.establish_context
Open slide detailBeat · SolutionLoop · Golden Circle
08
The slide illustrates a sequential therapeutic approach: THIO treatment followed by CPI therapy.present_solution
Open slide detail
09
Slide highlights a strategic partnership/traction milestone.show_traction
Open slide detail
10
The chart demonstrates tumor volume reduction over time, highlighting the efficacy of the THIO + Atezo combination.show_traction
Open slide detail
11
The slide outlines a multi-part clinical trial process from Part A (Safety) through Part B (Efficacy/Dose Selection) to a planned Expansion phase.plan_implementation
Open slide detail
12
The table compares a standard of care (Cyramza), a regulatory benchmark, and the company's own drug candidate (THIO-101).compare_peers
Open slide detail
13
Data cut of ongoing study THIO-101 as of 13Nov2023.compare_peers
Open slide detail
14
The slide uses a specific medical study to justify a change in clinical trial endpoint strategy.argue_timing
Open slide detail
15
Data cut as of 13Nov2023.compare_peers
Open slide detail
16
The chart tracks individual patient timelines, including disease progression, partial responses, and study outcomes.show_traction
Open slide detail
17
The slide outlines a multi-part clinical trial design (basket/umbrella) for a biotech drug candidate.plan_implementation
Open slide detail
18
The slide presents two line charts showing tumor volume reduction over time, highlighting 100% complete response (CR) and resistance to tumor rechallenge.show_traction
Open slide detail
19
The slide shows two line charts comparing tumor volume reduction across different treatment regimens in mouse models.show_traction
Open slide detail
20
The chart shows tumor volume over time, with the THIO group reaching 100% complete response (CR).show_traction
Open slide detail
21
The slide presents two line charts showing tumor volume over time, illustrating the efficacy of THIO in primary treatment and rechallenge scenarios.show_traction
Open slide detail
22
The slide outlines a clinical trial process flow involving SCLC and NSCLC patient baskets, immune activation, and subsequent combination therapies leading to a plan_implementation
Open slide detail
23
transition
Open slide detail
24
The slide highlights both regulatory exclusivity (NCE) and a multi-layered patent strategy extending into the 2040s.present_solution
Open slide detail
25
Includes headshots, professional summaries, and a grid of logos representing past company affiliations.other
Open slide detailBeat · Team
26
The slide contrasts the massive combined market of established CPIs ($42B) with the smaller market share of Libtayo ($0.5B) to frame the opportunity for partnersize_opportunity
Open slide detailBeat · Market Size
27
The slide uses market cap data to establish valuation benchmarks and cites recent M&A activity as a validation of the sector's value.compare_peers
Open slide detailBeat · Competition
28
The slide uses a grid-based timeline layout to map specific clinical events to calendar years.plan_implementation
Open slide detail
29
appendix
Open slide detail
30
Includes details on options, warrants, and insider ownership percentages.analyze_data
Open slide detail
31
The slide shows a biological mechanism of action (MOA) validation using TIFs as a biomarker.analyze_data
Open slide detail